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nloaded frIn the 1990s, Hendra virus and Nipah virus (NiV), two closely related and previously unrecognized paramyxo-
viruses that cause severe disease and death in humans and a variety of animals, were discovered in Australia
and Malaysia, respectively. Outbreaks of disease have occurred nearly every year since NiV was first discovered,
with case fatality ranging from 10 to 100%. In the African green monkey (AGM), NiV causes a severe lethal
respiratory and/or neurological disease that essentially mirrors fatal human disease. Thus, the AGM represents
a reliable disease model for vaccine and therapeutic efficacy testing. We show that vaccination of AGMs with a
recombinant subunit vaccine based on the henipavirus attachment G glycoprotein affords complete protection
against subsequent NiV infection with no evidence of clinical disease, virus replication, or pathology observed
in any challenged subjects. Success of the recombinant subunit vaccine in nonhuman primates provides crucial
data in supporting its further preclinical development for potential human use.htt
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Hendra virus (HeV) first appeared in Australia in 1994, with infection
and fatal disease occurring in horses and humans. In total, two of
three infected horse handlers and 15 horses succumbed to the fatal
HeV disease (1). Nipah virus (NiV) appeared in peninsular Malaysia
in 1998 in pigs and pig farmers. By mid-1999, more than 265 human
cases of encephalitis, including 105 deaths, had been reported in Ma-
laysia, and 11 cases of either encephalitis or respiratory illness with
one fatality were reported in Singapore (1). Although HeV and NiV
emerged independently, further characterization demonstrated that
both viruses were paramyxoviruses that have similar biological, mo-
lecular, and serological properties that were distinct from those of
all other paramyxoviruses, and consequently, they were grouped
together as closely related viruses in the new Henipavirus genus (2).
The known natural reservoir hosts of both HeV and NiV are pteropid
fruit bats, commonly known as flying foxes, which do not exhibit clin-
ical disease when infected (3). Numerous flying fox species have anti-
bodies to HeV and NiV (4), and their vast geological range overlaps
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www.ScienNiVhave a broad species tropism, and in addition to infecting bats, they
can infect and cause disease, often with very high fatality rates, in a wide
range of species spanning six mammalian orders [reviewed in (5, 6)].
Fatal NiV outbreaks among people have occurred nearly annually
[reviewed in (7, 8)] since 2001, and all outbreaks have occurred in
Bangladesh or India, with the most recent appearance in January
2012 (9). Of significance, from 2001 to 2007, transmission of NiV from
bats to humans occurred in the absence of an intermediate animal
host, person-to-person transmission accounted for more than half of
the identified NiV cases, and case fatality rates were typically >75%
(8). In 2008 and 2009, there were three confirmed human HeV cases
including two fatalities (10, 11); in 2010, two individuals had high-risk
HeV exposure (12); and in 2011, an unprecedented 18 independent
HeV outbreaks were reported in Australia (13, 14), which included nu-
merous horse fatalities and cases of human exposure and the first ev-
idence of HeV seroconversion in a farm dog (15). HeV spillovers into
horses has since occurred on three occasions in 2012, first in early
January outside the typical July-to-September period of most cases
(16) and, most recently, in May with two simultaneous but geograph-
ically distant occurrences in Queensland resulting in additional equine
mortalities and several low-risk human exposures (17).
Currently, there are no approved therapeutics or vaccines for HeV
or NiV [reviewed in (7, 18)]. Traditionally, host antibody responses
have been the immunological measure of vaccine efficacy, and histor-
ically, most neutralizing antibodies to enveloped viruses are directed
against surface glycoproteins. In recent years, a recombinant soluble
form of the HeV attachment (G) envelope glycoprotein (sGHeV) (19)
has proven highly effective in protecting small animals from lethal
NiV and HeV challenge when used as an immunogen (20, 21). These
successful efficacy trials in concert with serological studies from
naturally infected animals (22) have suggested that sGHeV is an ideal
henipavirus vaccine immunogen. More recently, the development
of nonhuman primate (NHP) models of NiV and HeV infection
and disease were reported (23, 24). In these studies, infection ofceTranslationalMedicine.org 8 August 2012 Vol 4 Issue 146 146ra107 1






 African green monkeys (AGMs) was uniformly lethal, and disease es-
sentially mirrored the severe clinical symptoms and associated pathol-
ogy seen in humans, with widespread systemic vasculitis and parenchymal
lesions in multiple organ systems, in particular, lungs and brain, along
with the development of clinical signs directly associated with damage
of these organs. These AGM models currently represent the best ani-
mal models of human henipavirus–mediated disease (6), and evaluat-
ing vaccine candidates in them will likely be required by the U.S. Food
and Drug Administration (FDA) before the licensure of any vaccine for
future human use. Recently, a highly efficacious human monoclonal
antibody was found to protect NiV-infected ferrets and HeV-infected
AGMs from lethal disease when administered after virus challenge
(25, 26). In these studies, all animals treated after exposure recovered
from infection and survived, representing the first post-exposure henipa-
virus therapeutic demonstrating in vivo efficacy. Clinical illness and
transient viremia were noted in animals that received therapy 24 hours
after exposure, and log increases in antibody titer were detected in all
surviving animals, further indicating virus replication in protected ani-
mals. Here, we report the prophylactic efficacy of the sGHeV vaccine
using the lethal NiV AGM challenge model. The data demonstrate
that sGHeV vaccination elicits highly neutralizing antibody responses
that prevent NiV infection and disease in AGMs. The immunogenicity
of recombinant sGHeV, its ability to elicit cross-reactive neutralizing
antibody titers, and its exceptional protective efficacy in NHPs dem-
onstrate its prophylactic potential and provide crucial data in sup-
porting potential licensure for future use in humans. by guest on June 3, 2019
ciencem
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Vaccination and NiV challenge
Previously, we have demonstrated that intratracheal inoculation of
AGMs with 1 × 105 TCID50 (median tissue culture infectious dose)
of NiV caused a uniformly lethal outcome (23, 24). Rapidly progres-
sive clinical illness was noted in these studies. Clinical signs included
severe depression, respiratory disease leading to acute respiratory dis-
tress, severe neurological disease, and severely reduced mobility, and
time to reach approved humane endpoint criteria for euthanasia
ranged from 7 to 12 days. Here, we sought to determine whether vac-
cination with sGHeV could prevent NiV infection and disease in AGMs.
A timeline of the vaccination schedule, challenge, and biological spec-
imen collection days is shown in Fig. 1.
Doses of 10, 50, or 100 mg of sGHeV were
mixed with alum and CpG moieties as
described in Materials and Methods.
Each vaccine formulation was adminis-
tered intramuscularly to three subjects
on day 0 (prime) and again on day 21
(boost), and one control subject (AGM 9)
received an adjuvant-alone prime and
boost on the same days. Vaccine formu-
lations were delivered intramuscularly to
mimic the most common human vaccine
delivery route. Moreover, intramuscular
injection was consistent with the deliv-
ery route used in previous sGHeV effica-
cy studies. On day 42, all subjects were
inoculated intratracheally with 1 × 105www.ScienTCID50 NiV. The control subject (AGM 9), consistent with historical
controls (23), showed loss of appetite, severe sustained behavioral
changes (depression, decreased activity, and hunched posture), de-
creases in platelet number, and a gradual increase in respiratory rate
at end-stage disease. Subsequently, AGM 9 developed acute respirato-
ry distress and had to be euthanized according to the approved hu-
mane endpoints on day 10 after infection. In contrast, none of the
vaccinated subjects had clinical disease and all survived until the
end of the study. A Kaplan-Meier survival graph is shown in Fig. 2.
NiV-mediated disease in the control subject
Gross pathological changes in the control subject were consistent with
those found previously in NiV-infected AGMs (23). Splenomegaly and
congestion of blood vessels on the surface of the brain were present,
and all lung lobes were wet and heavy. NiV RNA and infectious virus
were not recovered from AGM 9 blood samples, and there was no
evidence of viremia. Serum immunoglobulin (Ig) levels were deter-
mined using previously published multiplexed microsphere assays
(26), and AGM 9 had considerable levels of NiV G–specific IgM
and detectable NiV G–specific IgG and IgA (fig. S1A). Conversely,
NiV fusion (F) glycoprotein–specific IgM was not detected in the con-
trol subject at any time, which is similar to previous HeV and NiV
challenge studies where animals that succumbed to lethal disease
did not seroconvert to HeV (20, 21) or NiV F. Moreover, recently, it
was demonstrated that in AGMs that survive infection, anti–HeV F
antibodies did not appear until day 13 after challenge (26). Further
analysis of tissue samples revealed an extensive NiV tissue tropism
similar to the widespread NiV infection seen previously in AGMs (23).
As demonstrated in fig. S1B, AGM 9 had NiV RNA in most tissues as
indicated, and infectious virus was recovered from numerous tissues.
Tissue sections were stained with hematoxylin and eosin or stained by
immunohistochemical techniques using a rabbit polyclonal antiserum
against recombinant NiV nucleoprotein as previously described (26).
Noteworthy lesions included interstitial pneumonia, subacute enceph-
alitis, and necrosis and hemorrhage of the splenic white pulp. Alveolar
spaces were filled by edema fluid, fibrin, karyorrhectic and cellular de-
bris, and alveolar macrophages. Multifocal encephalitis was character-
ized by the expansion of Virchow-Robins space by moderate numbers
of lymphocytes and fewer neutrophils. Smaller numbers of these in-
flammatory cells extended into the adjacent parenchyma. Numerous
neurons were swollen and vacuolated (degeneration) or were fragmentedFig. 1. Schematic diagram of sGHeV vaccination and NiV challenge schedule. Dates of sGHeV vaccination,
NiV challenge, and euthanasia are indicated by arrows. Blood and swab specimens were collected on days
−42, −7, 0, 3, 5, 7, 10, 14, 21, and 28 after challenge as indicated (*). Gray text denotes challenge timeline;
black text denotes vaccination timeline. AGM numbers for subjects in each vaccine dose group and one
control subject are shown.ceTranslationalMedicine.org 8 August 2012 Vol 4 Issue 146 146ra107 2
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 with karyolysis (necrosis). Multifocal germinal centers of follicles in
splenic white pulp were effaced by hemorrhage and fibrin, as well as
small numbers of neutrophils and cellular and karyorrhectic debris.
These findings were consistent with necrosis and loss of the germinal
centers in the spleen. Representative tissue sections from AGM 9 lung
and brainstem are shown in fig. S1C. The extensive amounts of viral
antigen in the brainstem highlight the extensive damage NiV causes in
the central nervous system.
Protection of sGHeV-vaccinated subjects
All biological specimens, including all blood samples collected after
challenge and all tissues collected upon necropsy, were negative for
NiV RNA and infectious virus was not isolated from any specimen.
Upon closer examination of tissue sections from vaccinated subjects,
tissue architecture appeared normal and NiV antigen was not detected
in any tissue using immunohistochemical techniques. Representative
examples of tissue sections from the control and vaccinated subjects
are shown in Fig. 3. To further dissect the vaccine-elicited mechanisms
of protection, we measured serum and mucosal sGNiV- and sGHeV-
specific IgM, IgG, and IgA, as well as NiV and HeV serum neutrali-
zation titers in vaccinated animals. Ig levels were determined using the
multiplexed microsphere assay (26), and serum neutralization assays
were done as described previously (24). As demonstrated in Fig. 4, 7 days
before challenge, subjects receiving the lowest sGHeV dose had detect-
able antigen-specific serum IgM and the highest level of sGHeV-specific
serum IgG. Subjects given 50 mg of sGHeV also had detectable levels of
serum IgM and their highest levels of serum IgG 7 days before chal-
lenge. High–vaccine dose subjects had no detectable serum IgM, and
serum IgG levels were considerably lower on day −7 compared to
those of the other two groups. By the day of NiV challenge, serum
IgG levels in the high-dose subjects had increased and all vaccinated
subjects had similar IgG levels. Serum IgM levels did not change in
any subject after NiV challenge. Serum IgG levels decreased in the
medium-dose subjects the day of NiV challenge, and IgG levels de-
creased in low-dose subjects just after NiV challenge. IgG levels in-
creased in both of these groups by days 3 and 5 after infection butwww.Sciennever surpassed the IgG levels present 7 days before challenge, and
in both groups, titer decreased considerably by day 28 after infection.
Conversely, serum IgG levels in the high-dose group remained high
and were at their highest at day 28 after infection. Antigen-specific
serum IgA was detectable in all subjects after vaccination; however,
the levels were very low and pre- and post-challenge levels did not
appear to be meaningfully different (Fig. 4). A minimal increase in
mucosal antigen-specific IgA was detected in nasal swabs from low-
dose subjects on day 14 after infection; however, the levels were so low
that these mucosal antibodies likely played no role in preventing the
spread of NiV after challenge. Results from serum neutralization
tests (SNTs) are shown in Table 1. For most vaccinated subjects,
HeV-specific serum neutralization titer remained the same compared
to pre-challenge neutralization titers and decreased by day 28 after in-
fection. Slight increases in HeV-specific neutralization titers were ob-
served in two subjects that had the lowest pre-challenge HeV-specific
neutralization titer. Similarly, NiV-specific serum neutralization titer did
not increase by day 7 after infection compared to pre-challenge NiV-
specific neutralization titers, except in subjects that had the lowest titer
before challenge, and increases were only slight. By day 14 after infec-
tion, one low-dose and one high-dose subject had a log increase in
NiV-specific neutralization titer, and one medium-dose subject had
a log increase in NiV-specific neutralization titer by day 21 after in-
fection. For the remaining vaccinated animals, changes in NiV-specific
neutralization titers were either inconsistent (titer would increase and
then decrease) or not substantial (titer increased by three- to fourfold
but not more than a log). Previous post-exposure efficacy trials of a
henipavirus G–specific human monoclonal antibody in NiV-infected
ferrets and HeV-infected AGMs have demonstrated that in addition
to therapeutic antibody levels, a robust primary immune response to
the other viral surface glycoprotein (F) correlated with the recovery
from NiV- or HeV-mediated infection and disease (25, 26). Converse-
ly, sGHeV-vaccinated ferrets subsequently challenged with HeV do not
mount a robust primary immune response after HeV challenge, and
anti-F antibodies are almost undetectable (20, 21). To further assess
the primary immune response after NiV challenge in vaccinated AGMs,
we assayed plasma samples from NiV-infected AGMs for the presence
of NiV F–specific IgM. As demonstrated in fig. S2, minimal levels of
serum anti–NiV F IgM were detected in the low- and medium-dose
subjects on days 10 and 21 after infection, respectively, and these low
median fluorescence intensity (MFI) values suggest a very weak pri-
mary antibody response after NiV challenge. Serum anti–NiV F IgM
was not detected in the high-dose subjects, suggesting that these ani-
mals had little to no stimulation of the immune system, suggesting an
absence of circulating virus after challenge.
Although, collectively, the anti-NiV antibody data suggest that the
host’s immune systems responded to NiV challenge, the low levels or
absence of NiV F–specific IgM and the minimal changes in IgG and
neutralizing titer suggest that the primary immune response after NiV
challenge was not robust in vaccinated animals. Instead, the spread of
NiV in vivo was most likely controlled in all subjects by the presence
of NiV-specific neutralizing antibodies that were elicited by sGHeV
vaccination before NiV challenge. Although all vaccinated subjects
were protected from NiV infection and disease, the high dose of sGHeV
(100 mg) appeared to generate the most sustained IgG response, in-
creased NiV SNT titer on day 14 after infection in all animals, which
increased further by day 28, and the weakest primary immune re-
sponse after challenge suggesting the lowest levels of circulating virusFig. 2. Survival curve of NiV-infected subjects. Data from control subjects
(n = 2) and sGHeV-vaccinated subjects (n = 9) were used to generate the
Kaplan-Meier survival curve. Control included data from one additional his-
torical control subject. Vaccinated subjects received 10, 50, or 100 mg of
sGHeV administered subcutaneously twice. Average time to end-stage dis-
ease was 11 days in control subjects, whereas all vaccinated subjects sur-
vived until euthanasia at the end of the study.ceTranslationalMedicine.org 8 August 2012 Vol 4 Issue 146 146ra107 3
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 after challenge. Together, these data suggest that vaccination with the
high-dose sGHeV formulation affords near-sterilizing immunity to the
host. In the low- and medium-dose sGHeV vaccinations, although pro-
tection from infection and disease was impressive, IgG appeared to
wane by day 28 after challenge, and weak IgM responses to NiV F sug-
gest that undetectable amounts of virus were circulating in the host.
Complete protection of sGHeV-vaccinated AGMs from NiV infec-
tion and disease represents a major milestone toward licensure of an
NiV vaccine for potential human use. Demonstrating complete pro-
tection in an NHP model of NiV-mediated disease that closely
parallels human disease provides key efficacy data in a relevant species,
which is a critical component of any vaccine licensure and a definite
requirement of the FDA.DISCUSSION
Outbreaks of both HeV and NiV have been occurring on an annual
basis in Australia and Bangladesh, respectively, over the past several
years, and for both viruses, the dynamics of disease, emergence andwww.ScienceTranslationalMedicine.org 8transmission, appear to be changing. Re-
view of HeV and NiV human cases has
demonstrated that both viruses cause se-
vere respiratory and/or severe neurologi-
cal disease, and long-term neurological
sequelae or relapsing encephalitis has been
documented in HeV- and NiV-infected
individuals (11, 27, 28). In Bangladesh, di-
rect transmission of NiV from flying foxes
to humans appears to account for most
outbreaks and person-to-person transmis-
sion of NiV has been well documented
with high case fatality [reviewed in (8, 29)].
For HeV, human infection and exposures
have also increased; an extraordinary
number of independent spillover events
occurred between bats and horses in 2011,
and recently, the first case of HeV sero-
conversion in an Australian farm dog was
documented (14, 15). These alarming find-
ings are having major impacts and have led
to changes in practices in both Bangladesh
and Australia. In Bangladesh, individuals
have been encouraged to stop drinking
fresh date palm sap, an ancient tradition
(30, 31), and in Australia, veterinarians
are ceasing equine medicine to avoid HeV
exposure (32).
Developing effective countermeasures
for high-hazard pathogens such as HeV
and NiV is a complex process. Because
traditional clinical trials are not possible,
the efficacy of potential countermeasures
must be evaluated in multiple animal mod-
els where disease closely parallels human
disease and the pathogenic processes are
well understood. Additionally, the mech-
anism of protection must be elucidatedduring efficacy trials. To date, the efficacy of sGHeV has been evaluated
in two animal models of HeV-mediated disease, ferret (21) and equine
(33), and two animal models of NiV-mediated disease, feline (20) and
an NHP (presented here). In these studies, all vaccinated animals de-
veloped high levels of antigen-specific and cross-reactive NiV-specific
serum IgG and neutralizing antibodies before challenge and all ani-
mals were protected from HeV or NiV disease. Moreover, there was
no evidence of clinical disease or infectious virus in any vaccinated ani-
mal across all these efficacy trials. Various henipavirus strains, includ-
ing NiV-Malaysia, HeV-1994, and HeV-Redlands, were used in these
efficacy trials, and studies to evaluate protection against NiV-Bangladesh
still need to be completed; however, given the sequence homology
between NiV-Malaysia and NiV-Bangladesh and the demonstrated
cross-reactive protective immunity elicited by sGHeV, we would expect
sGHeV-vaccinated subjects to be protected from NiV-Bangladesh challenge.
Although efficacy trials have not yet been completed in HeV-infected
NHPs, sGHeV will most likely afford complete protection against homolo-
gous HeV challenge as it has been able to do in both cats and horses.
Due to the recent escalation and geographic spread of recurrent HeV
outbreaks in Australia, the use of the sGHeV immunogen described hereFig. 3. Absence of NiV antigen in sGHeV-vaccinated subjects. Lung, brainstem, and spleen tissue sections
were stained with an N protein–specific polyclonal rabbit antibody, and images were obtained at an orig-
inal magnification of 20×.August 2012 Vol 4 Issue 146 146ra107 4
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 as a veterinary vaccine is now in commercial development for use in
horses in Australia with an anticipated target date for availability some-
time in 2013 (17, 34). The immunogenicity and exceptional efficacy of
sGHeV in protecting NHPs against NiV-mediated disease represents awww.Scienmajor vaccine milestone toward licensure of a human vaccine, providing
strong justification for further development of sGHeV as a recombinant
subunit vaccine against NiV and HeV for potential human use, and a
single subunit vaccine against both viruses would be ideal.Table 1. HeV and NiV serum neutralization titers in vaccinated AGMs. Reciprocal serum dilution at which 50% of virus was neutralized.sGHeV doses (mg) AGMDay*−42 −7 7 14ceTranslatio28nalMedicine−42.org 8 Aug−7ust 20127Vol 4 Issue14146 146ra10728HeV NiV0† 9 <20 <20 24 ‡ ‡ <20 <20 <20 ‡ ‡10 16 <20 >2560 >2560 >2560 1074 <20 379 226 >2560 214717 <20 >2560 >2560 905 537 <20 134 134 537 45318 <20 >2560 >2560 453 537 <20 189 134 189 45350 13 <20 >2560 >2560 >2560 757 <20 379 189 189 45314 <20 1514 >2560 >2560 537 <20 28 47 226 13415 <20 2147 757 >2560 905 <20 67 95 757 1074100 10 <20 >2560 2147 1810 453 <20 67 113 268 45311 <20 >2560 >2560 >2560 1514 <20 134 189 905 151412 <20 >2560 >2560 >2560 757 <20 189 226 >2560 1514*Day after NiV challenge. †Received adjuvant alone. ‡Not sampled; shading indicates increase in serum neutralization titer.Fig. 4. NiV- and HeV-specific Ig in vaccinated subjects. Serum and nasal
swabs were collected from vaccinated subjects, and IgG, IgA, and IgM re-
(n = 3) were assayed individually, and the mean of microsphere MFIs
was calculated, which is shown on the y axis. Error bars represent thesponses were evaluated using sGHeV and sGNiV multiplexed microsphere
assays. Sera or swabs from subjects in the same vaccine dose groupSEM. Serum sG-specific IgM, IgG, and IgA are shown in black (sGHeV and
sGNiV), and mucosal sG-specific IgA is shown in gray (sGHeV and sGNiV).5
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 MATERIALS AND METHODS
Statistics
Conducting animal studies, in particular NHP studies, in biosafety lev-
el 4 (BSL-4) severely restricts the number of animal subjects, the vol-
ume of biological samples that can be obtained, and the ability to
repeat assays independently, thus limiting statistical analysis. Conse-
quently, data are presented as the means or medians calculated from
replicate samples, not replicate assays, and error bars represent the SD
across replicates.
Viruses
NiV-Malaysia (GenBank no. AF212302) was provided by the Special
Pathogens Branch of the Centers for Disease Control and Prevention
(Atlanta, GA). NiV was propagated and titered on Vero cells as de-
scribed for HeV in (24). All infectious virus work was performed in
the BSL-4 of the Division of Intramural Research, National Institute of
Allergy and Infectious Diseases (NIAID), National Institutes of Health
at the Rocky Mountain Laboratories (RML; Hamilton, MT), according
to the Standard Operating Protocols (SOPs) approved by the Institu-
tional Biosafety Committee.
Vaccine formulation
Three vaccine formulations of sGHeV were used (10, 50, or 100 mg).
Production and purification of sGHeV were done as previously described
(21). Each vaccine formulation also contained Allhydrogel (Accurate
Chemical & Scientific Corporation) and CpG oligodeoxynucleotide
(ODN) 2006 (InvivoGen) with a fully phosphorothioate backbone.
Vaccine doses containing a fixed amount of ODN 2006, varying
amounts of sGHeV, and aluminum ion (at a weight ratio of 1:25) were
formulated as follows: 100-mg dose: 100 mg of sGHeV, 2.5 mg of alumi-
num ion, and 150 mg of ODN 2006; 50-mg dose: 50 mg of sGHeV, 1.25 mg
of aluminum ion, and 150 mg of ODN 2006; and 10-mg dose: 10 mg of
sGHeV, 250 mg of aluminum ion, and 150 mg of ODN 2006. For all
doses, Allhydrogel and sGHeV were mixed first before ODN 2006
was added. Each vaccine dose was adjusted to 1 ml with phosphate-
buffered saline (PBS), and mixtures were incubated on a rotating
wheel at room temperature for at least 2 to 3 hours before injection.
Each subject received the same dose of 1 ml for prime and boost, and
all vaccine doses were given via intramuscular injection.
Animals
Ten young adult AGMs (Chlorocebus aethiops), weighing 4 to 6 kg
(Three Springs Scientific Inc.) were caged individually. Subjects were
anesthetized by intramuscular injection of ketamine (10 to 15 mg/kg)
and vaccinated with sGHeV by intramuscular injection on day −42
(prime) and day −21 (boost). Vaccine formulations are described be-
low. Three subjects received two doses of 10 mg (AGM 16, AGM 17,
and AGM 18), three subjects received two doses of 50 mg (AGM 13,
AGM 14, and AGM 15), three animals received two doses of 100 mg
(AGM 10, AGM 11, and AGM 12), and one subject (AGM 9) received
adjuvant alone. On day 0, subjects were anesthetized and inoculated
intratracheally with 1 × 105 TCID50 of NiV in 4 ml of Dulbecco’s min-
imum essential medium (DMEM) (Sigma-Aldrich). Subjects were anes-
thetized for clinical examinations including temperature, respiration
rate, chest radiographs, blood draw, and swabs of nasal, oral, and rec-
tal mucosa on days 0, 3, 5, 7, 10, 14, 21, and 28 after infection, and
clinical examinations were performed as previously described (35).www.ScienThe control subject (AGM 9) had to be euthanized according to the
approved humane endpoints on day 10 after infection. All other sub-
jects survived until the end of the study and were euthanized on day
28 after infection. Upon necropsy, various tissues were collected for
virology and histopathology. Tissues sampled include conjunctiva,
tonsil, oro/nasopharynx, nasal mucosa, trachea, right bronchus, left
bronchus, right lung upper lobe, right lung middle lobe, right lung
lower lobe, left lung upper lobe, left lung middle lobe, left lung lower
lobe, bronchial lymph node (LN), heart, liver, spleen, kidney, adrenal
gland, pancreas, jejunum, colon transversum, brain (frontal), brain
(cerebellum), brainstem, cervical spinal cord, pituitary gland, mandib-
ular LN, salivary LN, inguinal LN, axillary LN, mesenteric LN, urinary
bladder, testes or ovaries, and femoral bone marrow. Vaccination was
done under BSL-2 containment. NiV challenge experiments were con-
ducted under BSL-4 containment, and approval for all experiments
was obtained from the Institutional Animal Care and Use Committee
of the RML. All animal work was performed by a certified staff in an
Association for Assessment and Accreditation of Laboratory Animal
Care–approved facility at RML.
Specimen processing
Blood was collected in EDTA, sodium citrate, or serum Vacutainers
(Beckton Dickinson). Immediately after sampling, 140 ml of blood was
added to 560 ml of AVL viral lysis buffer (Qiagen Inc.) for RNA extrac-
tion. Serum was frozen for chemical and serological assays. For tissues,
about 100 mg was stored in 1 ml of RNAlater (Qiagen Inc.) for a
minimum of 24 hours to stabilize RNA, and about 100 mg was stored
for virus isolation. For tissues stored in RNAlater, RNAlater was com-
pletely removed and tissues were homogenized in 600 ml of RLT buffer
in a 2-ml cryovial with Qiagen tissue lyser and stainless steel beads. An
aliquot representing about 30 mg was added to a fresh RLT buffer (fi-
nal volume of 600 ml) (Qiagen Inc.) for RNA extraction. All blood sam-
ples in AVL viral lysis buffer and tissue samples in RLT buffer were
removed from the BSL-4 laboratory with approved SOPs. RNA was
isolated from blood and swabs with the QIAamp Viral RNA Kit (Qiagen
Inc.) and from tissues with the RNeasy Mini Kit (Qiagen Inc.) ac-
cording to the manufacturer’s instructions supplied with each kit.
Sera and mucosa antigen-specific antibody assays
Sera or mucosal swabs were inactivated by g irradiation (50 mGy; 1 Gy =
100 rads). The sG-specific Ig levels were determined with previously
published multiplexed microsphere assays (26). Antibodies to the
fusion (F) glycoprotein were measured in NiV-infected subjects simul-
taneously by including a recombinant soluble NiV F (sFNiV) glycoprotein–
coupled microsphere in the assay. Coupling of sF to microsphere 43
(Luminex Corporation) was done as described previously (26). Sera
were diluted 1:1000 for IgG assays and 1:100 for IgA and IgM assays;
swabs were assayed neat, and biotinylated goat anti-monkey IgG, IgA,
and IgM (Fitzgerald Industries International) were diluted 1:500. As-
says were performed on a Luminex 200 IS machine equipped with Bio-
Plex Manager Software (v. 5.0) (Bio-Rad Laboratories Inc.). MFI and
the SD of fluorescence intensity across 100 beads were determined for
each sample. The mean MFI was calculated for subjects in the same
vaccine dose group and results were plotted as the means ± SEM.
NiV and HeV SNTs
Neutralization titers were determined by microneutralization assay.
Briefly, sera were heat-inactivated at 56°C for 1 hour, serially dilutedceTranslationalMedicine.org 8 August 2012 Vol 4 Issue 146 146ra107 6
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 twofold, and incubated with 100 TCID50 of NiV or HeV for 1 hour
at 37°C. Virus and antibodies were then added to a 96-well plate with
2 × 104 Vero E6 per well in four wells per antibody dilution. Wells
were checked for cytopathic effect (CPE) 3 days after infection, and
the 50% neutralization titer was determined as the serum dilution at
which at least 50% of wells showed no CPE.
NiV TaqMan polymerase chain reaction
NiV nucleocapsid (n) gene–specific primers, an NiV n gene–specific probe
(25), and Qiagen QuantiFast Probe real-time RT-PCR (real-time reverse
transcription–polymerase chain reaction) kits were used according to
the manufacturer’s protocols. RNA from specimens was assayed once
(n = 1) in triplicate with a Bio-Rad CFX96 Real-Time System. All reac-
tions contained 2 ml of RNA; master mixes were set up according to
the manufacturer’s protocols, and each reaction was done in a total
volume of 25 ml. For blood, 2 ml of RNA represented 4.7 ml of whole
blood, and for tissues, 2 ml of RNA represented 1.2 mg of tissue. To ac-
count for plate-to-plate variation and to quantify NiV RNA in biological
samples, a standard curve of NiV RNA, isolated from the original NiV
inoculum, was run on each TaqMan plate. Inoculum-purified RNA was
diluted such that 2 ml represented 1.8, 188, or 1880 TCID50 NiV of the
original inoculum. NiV RNA standards were assayed in triplicate, and
the average Ct was set to a relative n gene expression value of 1, 10, and
100, respectively. Sample Ct values were analyzed against known Ct
values generated from the standard curve of NiV RNA, and a relative
NiV n gene expression value was extrapolated from the standard curve
for each sample replicate. Ct value analysis was done with Bio-Rad CFX96
Real-Time Software, and data are shown as the mean relative NiV n
gene expression level ± SD.
NiV isolation
Vero cells were seeded in 24-well plates in DMEM containing 10% fetal
calf serum (FCS), penicillin (100 U/ml), and streptomycin (100 mg/ml).
Tissues were weighed and homogenized (1:10 weight/volume in PBS)
in a 2-ml cryovial for 8 min with Qiagen tissue lyser and stainless steel
beads. Homogenates were clarified by centrifugation and diluted 1:10
with DMEM containing 1% FCS, penicillin (100 U/ml), and strepto-
mycin (100 mg/ml; DMEM-1). Duplicate wells were inoculated with
200 ml of a 1% tissue homogenate and incubated at 37°C. One well
was incubated for 30 min and one well was incubated overnight; both
were washed once with PBS and cultured in 1 ml of DMEM-1. Cul-
tures were examined for the presence or absence of syncytia/CPE for
5 days. Negative samples were passaged twice onto new cells before
being deemed negative.
Histopathology and immunohistochemistry
Necropsy was performed on all subjects. Tissue samples of all ma-
jor organs were collected for histopathologic and immunohisto-
chemical examination and were immersion-fixed in 10% neutral
buffered formalin for at least 7 days in BSL-4. Subsequently, formalin
was changed; specimens were removed from BSL-4 under approved
SOPs, were processed in BSL-2 by conventional methods, and em-
bedded in paraffin and sectioned at a thickness of 5 mm. Tissues for
immunohistochemistry were stained on the Discovery XT automated
stainer (Ventana Medical Systems Inc.) with an anti-Nipah nucleo-
protein antibody (1:5000) and the DAB Map Detection Kit (Ventana
Medical Systems Inc.). Nonimmune rabbit IgG was used as a negative
staining control.www.ScienSUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/4/146/146ra107/DC1
Fig. S1. NiV-mediated disease in the control subject.
Fig. S2. NiV F–specific IgM in vaccinated subjects.REFERENCES AND NOTES
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one step closer to clinical trials in human subjects.
demonstrate the feasibility of using immunization to prevent infection with Nipah virus and advance the vaccine
monkey quickly develops diffuse organ involvement and lethal disease, consistent with historic data. These results 
find that even the lowest dose they use provides full protection from Nipah virus challenge. In contrast, the control
infection in the monkeys. The animals are vaccinated with this glycoprotein at a range of doses, but the authors 
Here, a recombinant vaccine made from the attachment envelope glycoprotein of Hendra virus is used to prevent
involvement of the lungs and brain, and multiple other organ systems, leading to a universally lethal outcome. 
Nipah virus infection in African green monkeys results in symptoms similar to human disease, with severe
virus in a nonhuman primate model.
. show that a vaccine targeting both viruses shows full protection against Nipahet alcurrently exists. Now, Bossart 
nearly every year, particularly in Bangladesh, India, and Australia, and no effective treatment or prevention method
is known for person-to-person transmission. Since their discovery in the 1990s, outbreaks have been reported 
Nipahhumans and a wide range of other species, including domestic animals such as horses, pigs, and dogs; and 
rates approaching 100%. The recently discovered (and closely related) Nipah and Hendra viruses can infect
suspected that the furry fruit-loving bats carried deadly viruses that can cause human epidemics with mortality 
As people expanded their settlements further and further into the flying fox territory, no one could have
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